• Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials 

      Jørgensen, Kristin Kaasen; Goll, Guro Løvik; Sexton, Joe; Bolstad, Nils; Olsen, Inge C.; Asak, Øivind Wessel; Berset, Ingrid Prytz; Blomgren, Ingrid; Dvergsnes, Katrine; Florholmen, Jon; Frigstad, Svein Oskar; Henriksen, Magne; Hagfors, Jon; Huppertz-Hauss, Gert; Haavardsholm, Espen Andre; Klaasen, Rolf Anton; Moum, Bjørn; Noraberg, Geir; Prestegård, Ulf; Rydning, Jan Henrik; Sagatun, Liv; Seeberg, Kathrine; Torp, Roald; Vold, Cecilia; Warren, David J.; Ystrøm, Carl Magnus; Lundin, Knut Erik Aslaksen; Kvien, Tore Kristian; Jahnsen, Jørgen (Peer reviewed; Journal article, 2020)
      Background: The NOR-SWITCH main and extension trials demonstrated that switching from originator to biosimilar infliximab (CT-P13) is efficacious and safe across six diseases. However, a subgroup analysis of Crohn's disease ...